Laboratory and clinical evaluation of RU 28965 in respiratory infections

Yoshiteru Shigeno, Tomokazu Kakazu, Kazunori Tamaki, Hiroshi Fukuhara, Mustsuko Miyagi, Hiroki Nakamura, Hiroshi Kaneshima, Katsuyoshi Shimoji, Keizo Kitsukawa, Kenji Mori, Yutoku Kinjo, Atsushi Saito, Isamu Nakasone, Masayuki Taira, Nobuchika Kusano, Seitetsu Hokama, Yuei Irabu, Morio Oshiro

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

RU 28965, a new macrolide antibiotic, was basically and clinically evaluated with the following results. 1. Antimicrobial activity: the minimum Inhibitory concentrations (MICs) of RU 28965 against a total 134 strains consisting of 12 standard strains and 122 clinical isolates (6 species) were compared with those of erythromycin (EM) and cefaclor (CCL). RU 28965's antibacterial activity was equally or half as potent as that of EM against S.aureus, S.pneumoniae, B.catarrhalis and 1/2 or 1/4 as potent against H. influenzae. On the other hand, both antibiotics were poor against K.pneumoniae and P.aensginosa. 2. Clinical efficacy: RU 28965 was administered at a dailydose of 300 mg for 3~14 days to 15 patients with various respiratory infections. Clinical response was good 9, fair 2, poor 2 and not assessable 1; one dropped out. The overall efficacy rate was 69.2%(9/13 cases). Subjective and objective symptoms, hematological and biochemical data and renal functions were checked before and after administration of RU 28965. Three patients showed adverse reactions: diarrhea, eosinophilia, and minimal elevation of both S-GOT and S-GPT in 1 each. We therefore conclude that RU 28965 is a useful antibiotic in treating patients with respiratory infections.

Original languageEnglish
Pages (from-to)461-473
Number of pages13
JournalCHEMOTHERAPY
Volume36
DOIs
Publication statusPublished - 1988
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'Laboratory and clinical evaluation of RU 28965 in respiratory infections'. Together they form a unique fingerprint.

  • Cite this

    Shigeno, Y., Kakazu, T., Tamaki, K., Fukuhara, H., Miyagi, M., Nakamura, H., Kaneshima, H., Shimoji, K., Kitsukawa, K., Mori, K., Kinjo, Y., Saito, A., Nakasone, I., Taira, M., Kusano, N., Hokama, S., Irabu, Y., & Oshiro, M. (1988). Laboratory and clinical evaluation of RU 28965 in respiratory infections. CHEMOTHERAPY, 36, 461-473. https://doi.org/10.11250/chemotherapy1953.36.Supplement4_461